NIH chief: Comparative studies hold risk for personalized medicine
The use of comparative-effectiveness research as a means to reduce health care costs could jeopardize the advances in personalized medicine because such studies tend to miss groups of people who might benefit from a particular treatment, NIH Director Dr. Francis Collins said. "We need to be mindful of the goal of comparative-effectiveness research and not lose all that we have gained in understanding how individuals differ and how that could be factored into better diagnostics and preventive strategies," Collins said.
Reuters
| 10/27
This story published in FDLI SmartBrief on 11/02/2009
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|